Astellas and CoMentis to collaborate on beta-secretase inhibitors
Upon closing, CoMentis will receive an upfront payment of $80 million and an equity investment of $20 million. CoMentis has the opportunity to receive up to $660 million
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Under the recently executed material transfer agreement, BioCure will utilize ImmuneRegen’s Homspera for the development of a combination product composed of the potential wound-healing therapeutic Homspera and BioCure’s